Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 13/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955600 | 0.83 | KDM4E (0.41) | GSK3BDYRK1AWNT1KAT8KDM4E | |
| SCHEMBL3589343 | 0.82 | LGALS3 (0.37) | GSK3BDYRK1ALGALS3LGALS1WNT1 | |
| SCHEMBL15542994 | 0.81 | GSK3B (0.44) | GSK3BDYRK1ALGALS3LGALS1WNT1 | |
| SCHEMBL17795637 | 0.79 | GSK3B (0.46) | GSK3BDYRK1AWNT1 | |
| SCHEMBL22821500 | 0.78 | LGALS3 (0.37) | LGALS3LGALS1 | |
| SCHEMBL20868849 | 0.78 | KMO (0.44) | GSK3BDYRK1ALGALS3WNT1KDM4C | |
| SCHEMBL23346361 | 0.77 | LGALS3 (0.39) | LGALS3LGALS1 | |
| SCHEMBL17806601 | 0.75 | GSK3B (0.41) | GSK3BDYRK1AWNT1 | |
| SCHEMBL2682667 | 0.74 | PTGS2 (0.49) | GSK3BDYRK1AWNT1KDM4E | |
| SCHEMBL15729262 | 0.74 | DPP4 (0.41) | GSK3BDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | disclosed |
| US-20210138080-A1 | CONJUGATES | GLYKOS BIOMEDICAL OY (FI) | 2021-05-13 | — | — | US | disclosed |
| WO-2020210308-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020002765-A1 | CONJUGATES | GLYKOS BIOMEDICAL OY (FI) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138080-A1 | CONJUGATES | LGALS1, LGALS3BP, LGALS2 | GSK3B 4076/4885DYRK1A 2612/4885LGALS3 6/4885 |
| US-20230038373-A1 | STABILE CONJUGATE | CD2, TTL, DDOST | GSK3B 3998/4885DYRK1A 2304/4885LGALS3 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.